Bcl-2 inhibitor Navitoclax, Purity ≥98%

Synonym: 923564-51-6; Navitoclax; ABT-263; ABT-263 (Navitoclax); (R)-4-(4-((4'-Chloro-4,4-dimethyl-3,4,5,6-tetrahydro-[1,1'-biphenyl]-2-yl)methyl)piperazin-1-yl)-N-((4-((4-morpholino-1-(phenylthio)butan-2-yl)amino)-3-((trifluoromethyl)sulfonyl)phenyl)sulfonyl)benzamide; Bcl-2 inhibitor

MDL: MFCD12756219
CAS Number: 923564-51-6
Compound CID: 24978538

Product Size

5 mg; 10 mg; 25 mg; 50 mg; 100 mg

Price

Datasheet

Datasheet

MSDS

MSDS

Properties

Description

Navitoclax, soluble in DMSO and insoluble in ethanol and water, specifically inhibits the function of the anti-apoptotic proteins, thereby promoting apoptosis in cancer cells. It targets Bcl-xL, Bcl-2, Bcl-w, A1, and Mcl-1.

Molecular Weight

974.6

Molecular Formula

C₄₇H₅₅ClF₃N₅O₆S₃

Targets

Bcl-xL: ≤0.5 nM (Ki); Bcl-2: ≤1 nM (Ki); Bcl-w: ≤1 nM (Ki); A1: 354 nM (Ki); Mcl-1: 550 nM (Ki)

Form

Lyophilized powder

Purity

≥98%

Solubility

DMSO: 89 mg/mL (91.31 mM); Water: Insoluble; Ethanol: Insoluble

Identity

Confirmed by NMR/HPLC/MS.

Stability

The product is stable for three years when stored at the recommended temperature in lyophilized powder.

Applications

Navitoclax can be used to study in the context of hematologic malignancies and some solid tumors.

Storage

Store at -20ºC.